Travere Therapeutics
TVTXTVTX · Stock Price
Historical price data
Overview
Travere Therapeutics is a San Diego-based biopharma leader dedicated to rare diseases, particularly in nephrology and metabolism. The company has successfully transitioned to commercial operations with a fully approved therapy for IgA nephropathy (IgAN) and a late-stage pipeline targeting conditions like focal segmental glomerulosclerosis (FSGS) and classical homocystinuria (HCU). Its strategy leverages deep community engagement and scientific expertise to navigate complex development pathways and establish new standards of care in niche markets.
Technology Platform
A specialized development and commercial model for ultra-rare diseases, integrating deep scientific expertise with patient-centric insights, strategic regulatory navigation, and community advocacy to efficiently advance therapies in niche areas.
Pipeline
14| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Sparsentan | Proteinuria | Approved | |
| Pegtibatinase | Homocystinuria | Phase 3 | |
| sparsentan + Irbesartan | Focal Segmental Glomerulosclerosis | Phase 3 | |
| Fosmetpantotenate + Placebo | Pantothenate Kinase-Associated Neurodegeneration | Phase 3 | |
| sparsentan + irbesartan + Dapagliflozin | Immunoglobulin A Nephropathy | Phase 3 |
Funding History
3FDA Approved Drugs
1Opportunities
Risk Factors
Competitive Landscape
In IgAN, Travere faces competition from Calliditas' Tarpeyo and a wave of novel therapies from Novartis (iptacopan, atrasentan). In FSGS, it is a leader in an untreated space with few late-stage competitors. In HCU, it is pioneering enzyme replacement therapy against standard of care and Moderna's mRNA candidate. Deep patient community ties provide a defensive moat.